LH/hCG-receptor expression may have a negative prognostic value in low-risk endometrial cancer
| Autor: | Daniela Moncini, Flavia Sorbi, Elisabetta Projetto, Annarosa Arcangeli, Viola Ghizzoni, Massimiliano Fambrini, Luca Mannini, Gianna Baroni, Serena Pillozzi, Francesco Mungai, Ivo Noci, Tiziano Lottini |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty medicine.medical_treatment Case Report Ileum LH/hCG-receptor biomarker endometrial cancer immunohistochemical analysis molecular analysis recurrence lcsh:RC254-282 03 medical and health sciences 0302 clinical medicine Recurrence Internal medicine medicine LH/hCG receptor Stage (cooking) Chemotherapy business.industry Endometrial cancer Immunohistochemical analysis Cancer medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Clinical trial 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis Biomarker (medicine) Immunohistochemistry business |
| Zdroj: | Frontiers in Oncology, Vol 6 (2016) Frontiers in Oncology |
| DOI: | 10.3389/fonc.2016.00190/full |
| Popis: | Introduction: A 51 years-old woman was diagnosed with endometrial cancer and underwent surgical staging. Pathologic evaluation showed a 2x1 cm G2 endometrioid endometrial cancer with a 30% myometrial deep invasion (FIGO stage 1A). The patient was classified as low-risk of recurrence and no adjuvant treatment was offered. Six months after surgery, the patient developed an early vescico-vaginal recurrence and chemotherapy treatment was started. Few months later a subsequent involvement of vaginal wall, ileum and omentum was detected and the patient underwent second surgery. Background: LH/hCG-receptor (LH/hCG-R) expression has been previously reported to be associated with an invasive phenotype in endometrial cancer cells. Moreover, in a preclinical mouse model of EC behaves as a pro metastatic molecular device. Discussion: We analysed the expression level of LH/hCG-R in cancer specimens collected during surgeries. Molecular and immunohistochemical analysis showed a strong expression of both mRNA and protein for LH/hCG-R in all specimens. Conclusion: LH/hCG-R expression may be assessed together with other clinicopathological parameters in order to better predict the risk of recurrence in low-risk endometrial cancer patients. Further clinical trials are warranted in order to validate LH/hCG-R as biomarker in endometrial cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|